Halozyme Therapeutics, Inc. (NasdaqGS:HALO) may look for M&A. Helen Torley said during the Goldman Sachs 45th Annual Global Healthcare Conference, "we're in a great position to be considering doing M&A. But because the business is strong, we're in no urgency to do M&A. And so what we would do is I'll give my usual [indiscernible] we'll take our time. We'll find the right opportunity that has got the ability to add to the profile of the company, adding revenue, adding durable revenue. And we're looking in the areas of drug delivery technologies.

But we're also looking outside that in adjacencies. Our business model is to be a leader in licensing technologies. I think we've demonstrated that, obviously, with great success with ENHANZE and core to that is our strength in IP.

We've demonstrated that recently with the expansion of our claims as it relates to ENHANZE. And so we're going to take our time. We're going to find the right opportunity as it relates to M&A. But we do think if we can find that, that will be the best way to return additional value to our shareholders using our capital".